Menu
Saving lifes
MATCH biosystems is an innovative IVD company focused on the research, development and commercialization of a new generation of in vitro diagnostic devices (IVD) faster, more reliable than the current solutions available and easy to use. We are developing a ready to use (RTU) portfolio with innovative diagnostic kits.
We develop innovative solutions able to improve healthcare outcomes by means of reducing mortality rates and being competitive enough to decrease the cost burden. At MATCH biosystems we want to afford doctors and patients with the most valuable asset… TIME.
Delayed diagnostics & non-specific treatments lead to high mortality rates on patients, but if patients could receive targeted treatment faster thanks to shorter diagnostic times the outcome will largely improve.
Fungal detection assay: no blood culture required. 300μL sample test.
Doctors won’t need to send samples to the lab to get the diagnostic anymore. In less than an hour from sample collection.
7 species: C. albicans, C. tropicalis, C. glabrata, C. krusei, C. parapsilosis, C. dubliniensis and C. auris.
Sensitivity > 95% | Specificity > 99% | Species ID =
Available diagnostics do not provide timely, accurate an affordable results.
750K/year
INCIDENCE CASES
40% mortality rate
60%
Producing increased adverse affects, resistances, length of stay and care costs.
34%
Mortality increase in patients with Invasive Candidiasis.
>$1B/year USA
$64K/patient worlwide median total cost.
$10-80k/patient worldwide mean range.
PhD in Nanomedicine & MBA
CEO and co-founder of MATCH biosystems.
His background includes a degree in Pharmacy and a PhD in Nanomedicine (both Cum Laude mention).
He has extensive experience in biomedical research and industrial property.
In 2019, together with Tech Transfer UPV fund, work began to exploit innovative knowledges in the IVD field.
After validation of the interest and feasibility of the project by BHV, it was decided in 2020 to jointly found the company MATCH biosystems.
Financial Controller Analyst at TTUPV
Chief Financial Officer.
Diego holds a degree in Mechanical Engineering from the Polytechnic University of Valencia.
Since 2016 he is part of Clave Mayor.
Diego works as a financial business analyst and participates in the activity of several companies, including MATCH biosystems.
Former CEO at iMicroQ
Strategy Director and member of the Board of Directors.
Bachelor’s degree in Chemical Engineering and Master’s degree in Nanotechnology.
International Business Management.
CEO and co-founder of iMicroQ, a company dedicated to the development of PoC technology for the integrated detection of pathogens, DNA and antigens, in the electrochemical assay platform QFast (pathogen detection in food safety).
More than 30 years of experience as Project Manager and new developments in companies in the petrochemical, food, paper and logistics sectors.
He has also participated in raising private funding for these companies and different startups.
Former CEO at iMicroQ
Strategy Director and member of the Board of Directors.
Bachelor’s degree in Chemical Engineering and Master’s degree in Nanotechnology.
International Business Management.
CEO and co-founder of iMicroQ, a company dedicated to the development of PoC technology for the integrated detection of pathogens, DNA and antigens, in the electrochemical assay platform QFast (pathogen detection in food safety).
More than 30 years of experience as Project Manager and new developments in companies in the petrochemical, food, paper and logistics sectors.
He has also participated in raising private funding for these companies and different startups.
PhD, CEO & co-founder at BHV Partners
President of the BoD. Professional with more than 20 years of management experience in biomedical companies.
Head of the Neurosciences department at Grupo Ferrer, including 2 clinical products and several patents and publications.
Director of innovation and member of the steering committee at Biocat – Biocluster of Catalonia- and director of entrepreneurship and innovation at Bellavista, legal, tax and business consulting firm.
Advisor to several biomedical start-ups. Mentor of acceleration programs such as The Collider, IQS Tech Factory, Caixaimpulse or BIND 4.0 among others.
Founder and CEO of BHV Partners, the first venture builder in healthcare in Southern Europe.
PhD in Biology and AMP Executive Education from ESADE and Wharton.
Professor at UPV
Scientific Director at CIBER-BBN
Co-founder at senolytx
Principal Investigator IDM
Co-founder and Scientific Advisory Board.
Professor and chair of the Universidad Politécnica de Valencia, and also serves as director of the Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina.
He brings extensive experience in research in the biomedical field to the development of the project.
Ramón led the project in the IDM group of the UPV that led to the patents transferred to MATCH.
Manager of Microbiology clinical area at HUiP La Fe
President of AEM
Co-founder and Scientific Advisory Board.
Head of the clinical area of Microbiology at the Hospital Universitario y Politécnico La Fe in Valencia.
He is also President of the Spanish Association of Mycology, and has extensive experience in the field of biomedicine research.
He participates in the project in the clinical aspects of the research.
Check out in LinkedIn
MATCH biosystems is a biotech startup developing a new generation of RTU diagnostic tests with main focus on high risk clinical infections.
We are building the best team to become the fastest-reliable solution available.
+34 626 660 555
Edificio Quórum IV - Parque Científico UMH
Av. de la Universidad de Elche, s/n
03202 Elche (Alicante, ESPAÑA)
